The Situation

Hedera Dx, a Swiss techbio company accelerating access to precision oncology, launched a strategic €15 million Series A fundraising round to expand their commercial presence and advance their AI-driven liquid biopsy platform. With operations already spanning 11 European countries and an ambitious growth roadmap, Hedera Dx needed a trusted legal partner to navigate the complexities of multi-party deal structuring, investor negotiations and road to successful closing.

Our Approach: Comprehensive Legal Advise and Transaction Execution

We supported the Hedera Dx team in coordinating with a diverse investor group including Vsquared Ventures, Tesi, and existing backers such as Helsana HealthInvest and Inventure, aligning interests and finalizing terms that balanced growth capital with strategic control.

From legal due diligence through to transaction closing, Alfred provided end-to-end legal execution, allowing the Hedera Dx leadership team to focus now again on what mattered most: "building the infrastructure to make precision cancer care accessible to every patient and clinician globally," in the words of Tommi Lehtonen, CEO and co-founder of Hedera Dx.

The Impact

Hedera Dx closed its €15M Series A round with participation from top-tier European investors. The round positions the company to scale its innovative blood-based diagnostics platform and fuel the next phase of growth in precision cancer care. The signing and closing of the financing round was eventually completed with investor alignment and transaction efficiency.

Hedera Dx is uniquely positioned at the intersection of diagnostics and data to transform how oncology care is delivered globally. Their focus on enabling in-house hospital testing not only accelerates access to precision therapies but ensures more patients can benefit from tailored treatments earlier. This approach, as noted by Dr. Lise Rechsteiner, General Partner at Vsquared Ventures, addresses a critical systemic gap and sets the company on a path to becoming a leader in precision oncology outside the US combining robust diagnostics with real-world data infrastructure to reshape cancer care on a global scale.

“Alfred was a great partner in making sure this complex, high-stakes round closed smoothly and aligned with our long-term vision.” Tommi Lehtonen, CEO, Hedera Dx

The Team

Thierry Barbey, Founding Partner (Legal Advisory)

Thomas van Gammeren, Associate (Legal Advisory)

Sandro Stich, Senior Associate (Legal Advisory)